Overview

Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma

Status:
NOT_YET_RECRUITING

Trial end date:
2030-12-25

Target enrollment:

Participant gender:

Summary

This study is planned to prospectively evaluates the efficacy and safety of the zanubrutinib, obinutuzumab, and lenalidomide (ZGR) combination regimen in treatment-nave follicular lymphoma (FL) patients in a Chinese population.

Phase:

PHASE2

Details

Lead Sponsor:

Institute of Hematology & Blood Diseases Hospital, China

Treatments:

Lenalidomide
obinutuzumab